Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Edison Investment Research

02:57 EST 18th February 2019 | BioPortfolio

Here are the most relevant search results for "Edison Investment Research" found in our extensive news archives from over 250 global news sources.

More Information about Edison Investment Research on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Edison Investment Research for you to read. Along with our medical data and news we also list Edison Investment Research Clinical Trials, which are updated daily. BioPortfolio also has a large database of Edison Investment Research Companies for you to search.

Showing News Articles 1–25 of 810 from Edison Investment Research

Friday 15th February 2019

WANdisco (158355634WAND) - Increasing importance in the cloud ecosystem

Edison Investment Research - Technology - WANdisco: WANdisco’s designation as an Amazon Web Services (AWS) Advanced Technology Partner strengthens its position in the cloud ecosystem. We believe that a large, strategic deal remains in the pipeline, and the $17.5m capital raising (at a premium), should reassure potential partners. Our estimates are adjusted to reflect the new shares, but are ...

Deutsche Beteiligungs (DBAN) - Market sentiment weighing on portfolio value

Edison Investment Research - Investment trusts - Deutsche Beteiligungs: Deutsche Beteiligungs (DBAG) is making steady progress on its investment agenda, with three new acquisitions and several follow-on funding rounds totalling €40.2m completed in Q119. DBAG’s Fund VII has so far been able to allocate 56% of its investment commitments in seven transactions, reflecting solid portfolio r...

The Biotech Growth Trust (BIOG) - Industry backdrop remains favourable

Edison Investment Research - Investment trusts - The Biotech Growth Trust: The Biotech Growth Trust (BIOG) is managed by Geoff Hsu and Richard Klemm at OrbiMed Capital, one of the leading global healthcare asset managers. The year 2018 proved to be tough for the trust’s performance as biotech companies delivering negative news were heavily penalised, while those delivering good news went unr...

Taronis Technologies (MNGA) - Good start to FY19 sales

Edison Investment Research - General Industrials - Taronis Technologies: Taronis Technologies (formerly MagneGas) has announced its preliminary sales figures for January. These show the seven successive acquisitions made over the last year driving a fivefold year-on-year increase in monthly sales to $1.42m. Importantly, the figures show 42% growth compared with December, as activity has picked up ...

Thursday 14th February 2019

UmweltBank (UBK) - Awaiting an earnings inflection point

Edison Investment Research - Financials - UmweltBank: UmweltBank’s (UBK’s) preliminary FY18 numbers confirm the continuation of healthy lending business and deposit base growth, but also further interest margin compression. The additional tier 2 capital raised recently (€45m in total) provides a solid foundation for further loan book expansion, which together with gradually dimini...

InMed Pharmaceuticals (IN) - Entering the clinic by the end of the year

Edison Investment Research - Pharmaceuticals & healthcare - InMed Pharmaceuticals: InMed recently reported results for the second quarter of FY19 and is on track to bring INM-750 for epidermolysis bullosa (EB) into the clinic by the end of the year. The company recently completed two topical seven-day dose-ranging studies in pigs; the trials evaluated skin irritation, pharmacokinetics, histology a...

Wednesday 13th February 2019

GB Group (158355634GBG) - Expanding eIDV in the US

Edison Investment Research - Technology - GB Group: GB Group (GBG) has acquired IDology, a US identity verification business, for an enterprise value of $300m/£231m. It has placed 39m shares at 410p per share to fund £160m of the purchase price, with the remainder coming from a new credit facility. We estimate that the deal offers significant cross-selling potential and will boost GBG&...

Supermarket Income REIT (SUPR) - Visible income and growth potential

Edison Investment Research - Financials - Supermarket Income REIT: Supermarket Income REIT (SUPR) reported strong H119 earnings growth on the back of its growing portfolio, contracted RPI-linked rental uplifts, and well-controlled costs. The Q219 DPS was increased by 3.2%, in line with RPI. Rental growth also drove revaluation gains, sufficient to offset property acquisition costs in the period. ...

Oncology Venture (OV.ST) - Multiple programme updates

Edison Investment Research - Pharmaceuticals & healthcare - Oncology Venture: Oncology Venture (OV) continues to provide regular response data from its ongoing LiPlaCis Phase II trial in patients with metastatic breast cancer (mBC). To date, 33% of the top one-third sub-population delineated by the drug response predictor (DRP) achieved partial remission (PR) or better. The data also suggested tha...

Tuesday 12th February 2019

Alkane Resources (ALK) - Cashed up and hungry for investments

Edison Investment Research - Mining - Alkane Resources: Alkane Resources is a well-funded gold production company with A$73.7m in cash and no debt. It is seeking to leverage its cash balance and extensive expertise in gold mining and exploration through a strategy of investing in junior gold companies and projects that meet its investment criteria. Alongside this, the company is transitioning from...

Aberdeen Latin American Income Fund (ALAI) - Brighter prospects in Latin America

Edison Investment Research - Investment trusts - Aberdeen Latin American Income Fund: Aberdeen Latin American Income Fund (ALAI) gives investors exposure to both Latin American equities and government debt, and offers a 4.9% dividend yield. The company is managed by Aberdeen Standard Investments’ (ASI) global emerging markets equities and emerging market debt teams. They are cautiously optim...

Ebiquity (EBQ) - FY18 performance as anticipated

Edison Investment Research - Media - Ebiquity: Ebiquity’s year-end trading update indicates FY18 performance across both the continuing and the now-sold Advertising Intelligence businesses in line with management expectations. Given the delay and uncertainty over the disposal on the CMA referral, this is a solid outcome. FY19 will see some effect of overheads taking time to scale down follow...

Orexo (ORX) - The opioid use disorder patient journey

Edison Investment Research - Pharmaceuticals & healthcare - Orexo: Orexo’s FY18 results demonstrated continuing profitability derived from its lead product, Zubsolv, responsible for 21.7% y-o-y net sales growth driven by US Zubsolv Q418 prescription and revenue growth of 22% and 31.8%, respectively. The weakness in partnered products compared to our targets (although FY18 partnered sales wer...

Monday 11th February 2019

Aberdeen Latin American Income Fund (United Kingdom) - Brighter prospects in Latin America

Edison Investment Research - Investment trusts - Aberdeen Latin American Income Fund: Aberdeen Latin American Income Fund (ALAI) gives investors exposure to both Latin American equities and government debt, and offers a 4.9% dividend yield. The company is managed by Aberdeen Standard Investments’ (ASI) global emerging markets equities and emerging market debt teams. They are cautiously optim...

Friday 8th February 2019

Claranova (158355634CLA) - Organic growth across the board

Edison Investment Research - Technology - Claranova: Claranova reported 53% year-on-year revenue growth for Q219, with organic growth of 36%. All divisions contributed to organic growth, and the Canadian businesses acquired by Avanquest also performed well. While H119 revenue growth rates are ahead of our FY19 growth forecasts, we are maintaining estimates until further detail on profitability is ...

Thursday 7th February 2019

Edel (EDL) - Mixed media

Edison Investment Research - Media - Edel: Edel’s FY18 results showed a 6% sales increase and 7% improvement in EBITDA as it benefited from continued demand for vinyl and subsidiary Kontor New Media’s strong positioning in digital music. H2 was markedly tougher, as foreshadowed in the November trading update, reflecting pressure on the book publishing, one-off issues at Pandastorm Pict...

Aberdeen Standard Equity Income Trust (ASEI) - Optimism based on attractive valuations

Edison Investment Research - Investment trusts - Aberdeen Standard Equity Income Trust : Aberdeen Standard Equity Income Trust (ASEI, formerly Standard Life Equity Income Trust [SLET]) has been managed by Thomas Moore since November 2011. He is bullish on the long-term outlook for the trust as the yield on the portfolio is the highest since the end of the global financial crisis in 2009, suggestin...

Sunesis Pharmaceuticals (SNSS) - Vecabrutinib study advances

Edison Investment Research - Pharmaceuticals & healthcare - Sunesis Pharmaceuticals: In January 2019 Sunesis announced that its Phase Ib/II study of vecabrutinib for B-cell cancers advanced to the 100mg cohort. The company experienced a series of unavoidable clinical delays in the 50mg arm but was eventually able expand the number of clinical sites and overenroll the cohort. The 100mg dose is the ...

S&U (SUS) - Lending discipline tempers pace of growth

Edison Investment Research - Financials - S&U: S&U’s year-end trading statement indicated that FY19 results would be in line with expectations. Motor finance new business has slowed recently reflecting a combination of more intense competition and S&U’s maintenance of tighter credit criteria. As a result, FY20 starts with lower receivables than we had assumed, and it also seems...

Pelatro (158355634United Kingdom) - Big data analytics for telecoms

Edison Investment Research - Technology - Pelatro: Pelatro’s demonstration of its mViva marketing platform at a recent capital markets day revealed the scope of its big data analytics capabilities and interactive user interface. Ease of use by non-technical staff and the ability to quickly launch and analyse complex marketing initiatives are key differentiators. With its focus on client rete...

AJ Lucas Group (AJL) - Initial flow test results

Edison Investment Research - Oil & gas - AJ Lucas Group: Cuadrilla has become the first operator to have flowed gas from a horizontal shale gas exploration well in the UK. Initial results are encouraging, with recovered gas containing very high methane content (96%), no H2S and minimal CO2. Core samples suggest the Bowland shale is quartz rich, with low clay content and excellent properties for fr...

BCI Minerals (BCI) - Salt plus potash plus iron equals value

Edison Investment Research - Mining - BCI Minerals: BCI Minerals (BCI) has two major assets in Western Australia, namely its 100%-owned Mardie salt and potash project and a royalty interest in a producing iron ore mine (Iron Valley). Positive cash flow from the latter, in conjunction with c A$37m in cash, is being deployed to develop the former. Notwithstanding tough conditions in the iron ore mar...

SNP Schneider-Neureither & Partner (158355634SHF) - Significant operational improvements in H2

Edison Investment Research - Technology - SNP Schneider-Neureither & Partner: The primary focus in FY18 was on integrating the recent acquisitions and positioning the business for growth in anticipation of the emerging digitisation wave. FY18 revenues of c €131m were below our forecast of €137.9m. Nevertheless, H2 adjusted EBITDA saw a c €5.4m improvement over H1 reflecting signific...

Target Healthcare REIT (THRL) - Growing portfolio performing well

Edison Investment Research - Property - Target Healthcare REIT : During the three months to 31 December 2018 (Q219), Target made good progress with deploying available capital resources, including the £50m gross proceeds from the November share placement. The portfolio also continues to perform well, delivering a 2.3% quarterly NAV total return (9.5% annualised). The attractive dividend yiel...

Wednesday 6th February 2019

Stride Gaming (STR) - Trading broadly in line

Edison Investment Research - Travel & Leisure - Stride Gaming: Stride’s AGM confirmed that trading for the current financial year has been broadly in line, despite well documented regulatory headwinds. To counterbalance rising gaming taxes and other sector pressures, the group is implementing numerous cost-cutting initiatives, which will be key to hitting our FY19 EBITDA estimate. Looking ah...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks